Sandoz deal bolsters Aurobindo on derma
Aurobindo says it is continuing to focus its efforts on driving profitability through a “differentiated portfolio”, with a particular focus on dermatology, after striking in early September a US$1.0 billion deal to acquire Sandoz’ dermatology and oral-solids business in the US.
You may also be interested in...
Autonomous Sandoz Set To Be Tighter And Leaner
With an optimized manufacturing base, a narrower geographic footprint, and a tighter portfolio focus on differentiated biosimilars and hard-to-make generics, Novartis believes a more autonomous Sandoz division can remain an “integral part” of the Swiss group.
AAM Departures Lead To Change Of Chair For IGBA
The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.
Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.